• Seyed Mojtaba Sohrevardi, Fatemeh Shojaei Nasab, Mohammad Reza Mirjalili, Mohammad Bagherniya, Arefeh Dehghani Tafti, Mohammad Hossein Jarrahzadeh, Mahmoud Reza Azarpazhooh, Mohsen Saeidmanesh, Maciej Banach, Tannaz Jamialahmadi, and Amirhossein Sahebkar.
• Department of Clinical Pharmacy, Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
• Arch Med Sci. 2021 Jan 1; 17 (5): 1423-1428.

IntroductionDelirium is one of the most prevalent complications in intensive care unit (ICU) patients, which is related to worse clinical outcomes including a longer ICU stay, longer duration of mechanical ventilation, higher mortality rates and increased risk of cognitive impairment. Observational studies have suggested that statins might have a positive effect on delirium status of hospitalized patients. To date, there has been no trial assessing the effect of atorvastatin on delirium status in critically ill patients. Thus, the aim of the current study was to determine the efficacy of atorvastatin on delirium status of patients in the ICU.MethodsIn this randomized, double-blind and controlled trial, a total of 90 patients in the general ICU who had delirium for at least 2 days were randomly divided into atorvastatin (40 mg/day) (n = 40) and control (n = 50) groups. Delirium status of the patients was determined twice a day at 10:00 a.m. and 18:00 p.m. using the Richmond Agitation-Sedation Scale (RASS).ResultsAdministration 40 mg/day of atorvastatin significantly reduced the mean RASS score and increased delirium-free days at both morning and afternoon time points compared to the control group (p < 0.05).ConclusionsAdministration of atorvastatin had a significant positive effect on delirium status in patients admitted to the ICU.Copyright: © 2019 Termedia & Banach.

5 keywords...

hide…